Skip to main content
Premium Trial:

Request an Annual Quote

Tripos' Sale of Discovery Unit to Provid on Shaky Ground as Suitor Struggles to Raise Enough Cash

NEW YORK (GenomeWeb News) — Tripos today said a deal to sell its Discovery Research branch to Provid Pharmaceuticals may fall through after Provid said it is unable to pull together the cash it needs to make the acquisition.
As a result, Tripos said it has begun talking with “other parties” that it said have shown interest in buying the DR business, although the company said it could not assure that another suitor could find the money either.
Tripos said in early January it intended to sell the research unit in a stock deal worth roughly $2 million as part of a liquidation plan.
Today, the struggling company said it is “doubtful” that Provid would be able to gather the necessary financing to complete the deal as planned.
But Tripos also said the companies would consider restructuring the terms of the deal to make it happen.
In January, the Nasdaq exchange notified Tripos that it faces delisting for failing to maintain the minimum market cap and minimum share bid price for 30 consecutive days.
Tripos in November said it would sell its Discovery Informatics business to a San Francisco-based Vector Capital for $26.5 million.

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.